Thomas O. Bergmeijer

A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI

Daniel M.F. Claassens, Gerrit J.A. Vos, Thomas O. Bergmeijer et al. · New England Journal of Medicine · 2019 · 624 citations · Full text

Medicine, Cardiology, Pharmacology +16

Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial

Marieke E. Gimbel, Khalid Qaderdan, Laura M. Willemsen et al. · The Lancet · 2020 · 350 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel

Dominick J. Angiolillo, Davide Capodanno, Nicolas Danchin et al. · JACC: Cardiovascular Interventions · 2020 · 163 citations

Pharmacy, Pharmacology, Pharmacotherapy +11

Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients

Joshua P. Lewis, Joshua Backman, Jean‐Luc Reny et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 2019 · 101 citations · Full text

Medicine, Cardiology, Pharmacology +17

Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting

Heleen Bouman, Ankie M. Harmsze, Jochem W. van Werkum et al. · Heart · 2011 · 95 citations

Medicine, Cardiology, Pharmacology +17